Elevage Medical Technologies is dedicated to supporting medical device companies that can meaningfully improve health outcomes & quality of life for patients.
Mentions in press and media 6
| Date | Title | Description |
| 22.10.2024 | Nuclera: Biotech Company Raises $75 Million For Accelerating Protein Expression | Nuclera, the biotechnology company accelerating protein expression and purification workflows through its benchtop protein system, announced it had completed a $75 million financing round (circa £57 million). The funding round was led by El... |
| 17.10.2024 | Nuclera's $75 Million Leap: A New Era for Protein Discovery | In the world of biotechnology, speed is everything. Nuclera, a Cambridge-based biotech company, has just secured a $75 million Series C funding round. This significant investment is a game-changer, pushing the boundaries of protein discover... |
| 16.10.2024 | Nuclera raises $75M Series C for eProtein discovery system | Biotech Nuclera has raised a $75 million Series C financing round. This brings the company’s funding to over $140 million. The company is accelerating protein expression and purification workflows through its benchtop protein system, eProte... |
| 16.10.2024 | Nuclera closes $75 million USD financing | Series C round led by Elevage Medical Technologies. Funding will accelerate the commercialization of Nuclera’s eProtein Discovery platform, to optimize protein expression and purification workflows within research labs globally. Series C ro... |
| 19.08.2024 | Revolutionizing Healthcare: Moximed and PayZen Lead the Charge | In the evolving landscape of healthcare, two companies are emerging as beacons of innovation: Moximed and PayZen. Both are tackling significant challenges in the medical field, albeit from different angles. Moximed is addressing the physica... |
| 17.08.2024 | Moximed: $91 Million (Series D) Closed To Improve Knee Osteoarthritis Care | Moximed, an innovative medical device company with a goal of improving the standard of care for people with knee osteoarthritis (OA), announced the closing on $61 million of Series D preferred stock financing with an option to close on up t... |